Michael J. Overman

The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

(2023)10.1158/2767-9764.c.6975005.v1

Top 100%

0DataRank

Top 100%0 citations

Jane V. Thomas, Kaysia Ludford, Jason Willis, Victoria Serpas Higbie, Kanwal Raghav +15 more

Papers

Driven by 63 papers — median percentile 0. Top paper: “Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting”.

Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2403

N/A

1.5DataRank · unranked

34 citations

Rajyalakshmi Luthra, Yusha Liu, Dzifa Y. Duose, Wonyul Lee, Neelima G. Reddy +20 more

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-004822

N/A

1.4DataRank · unranked

44 citations

Bettzy Stephen, Daniel D. Karp, Sarina A. Piha‐Paul, David S. Hong, D Jain +10 more

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-006822

N/A

1.3DataRank · unranked

52 citations

Anne Knisely, David Vining, Scott Kopetz, Michael J. Overman, Milind Javle +16 more

Integration of Remote Symptom and Biometric Monitoring Into the Care of Adult Patients With Cancer Receiving Chemotherapy—A Decentralized Feasibility Pilot Study

JCO Oncology Practice(2023)10.1200/op.22.00676

N/A

0.763DataRank · unranked

11 citations

Domenica A. Delgado, Yu-Li Lin, Danielle Geyen, Christopher J. Miller, Sanchita Jain +6 more

Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older

Pancreatology(2020)10.1016/j.pan.2020.01.005

N/A

0.561DataRank · unranked

41 citations

Jane E. Rogers, Kenneth R. Hess, Robert A. Wolff, Gauri R. Varadhachary, Milind Javle +7 more

Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer

British journal of surgery(2022)10.1093/bjs/znac050

N/A

0.529DataRank · unranked

33 citations

Michael G. White, Oliver Peacock, Harmeet Kaur, Sarah Palmquist, Nancy You +6 more

Preliminary Analysis of Liquid Biopsy after Hepatectomy for Colorectal Liver Metastases

Journal of the American College of Surgeons(2021)10.1016/j.jamcollsurg.2021.02.011

N/A

0.505DataRank · unranked

28 citations

Ching‐Wei D. Tzeng, Hop S. Tran Cao, Thomas A. Aloia, Timothy E. Newhook, Michael J. Overman +4 more

Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer

Cancer Cell(2025)10.1016/j.ccell.2025.08.002

N/A

0.477DataRank · unranked

23 citations

Christine M. Parseghian, Vahid Bahrambeigi, Nourhan Abdelfattah, Lianchun Xiao, Anjali Agrawal +28 more

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience

The Oncologist(2022)10.1093/oncolo/oyac162

N/A

0.464DataRank · unranked

21 citations

Jane E. Rogers, Hyunsoo Hwang, Wei Qiao, Lianchun Xiao, Arvind Dasari +11 more

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

Journal of Clinical Oncology(2025)10.1200/jco-24-01710

N/A

0.458DataRank · unranked

9 citations

Katherine A. Guthrie, Benjamin Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman +15 more

Phase I trial of single-photon emission computed tomography–guided liver-directed radiotherapy for patients with low functional liver volume

JNCI Cancer Spectrum(2024)10.1093/jncics/pkae037

N/A

0.340DataRank · unranked

6 citations

Franklin C. Wong, Beth Chasen, William D. Erwin, Prajnan Das, Emma B. Holliday +27 more

Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial

Journal of Pain and Symptom Management(2020)10.1016/j.jpainsymman.2020.12.023

N/A

0.292DataRank · unranked

6 citations

Veronica Puac, Zeena Shelal, Diane Liu, Rama Maddi, Ahmed O. Kaseb +6 more

Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps634

N/A

0.269DataRank · unranked

5 citations

J. Jack Lee, Brandon G. Smaglo, Dan Zhao, Michael Sangmin Lee, Robert A. Wolff +5 more

Inducing Hypermutability to Promote Anti–PD-1 Therapy Response

Cancer Discovery(2022)10.1158/2159-8290.cd-22-0492

N/A

0.245DataRank · unranked

3 citations

Michael J. Overman, Jason Willis

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps158

N/A

0.241DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer

Journal of Gastrointestinal Oncology(2022)10.21037/jgo-21-471

N/A

0.241DataRank · unranked

4 citations

Bryan K. Kee, Michael J. Overman, Arvind Dasari, Kanwal Raghav, Benny Johnson +6 more

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps232

N/A

0.241DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps260

N/A

0.241DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Comprehensive genomic profiling of malignant peritoneal mesothelioma (MPeM) reveals key genomic alterations (GAs) distinct from malignant pleural mesothelioma (MPM).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8557

N/A

0.104DataRank · unranked

1 citations

Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu-Chin Fu, Anaís Malpica +13 more

RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3592

N/A

0DataRank · unranked

0 citations

Dongyun Yang, Hiba I. Dada, Van K. Morris, Xuemei Wang, Arvind Dasari +14 more

Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2616

N/A

0DataRank · unranked

0 citations

Nilofer S. Azad, Jennifer Lee, Jacob P. K. Gross, Michael J. Overman, Katrina Kao +14 more

Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0340

N/A

0DataRank · unranked

15 citations

Jane V. Thomas, Kaysia Ludford, Jason Willis, Victoria Serpas Higbie, Kanwal Raghav +15 more

Survival outcomes used to validate version 9 of the American Joint Committee on Cancer staging system for appendiceal cancer

CA A Cancer Journal for Clinicians(2023)10.3322/caac.21806

N/A

0DataRank · unranked

22 citations

Amanda E. Browner, Joseph H. Cotler, Heidi Nelson, Sanjay Kakar, Norman J. Carr +7 more

Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad095

N/A

0DataRank · unranked

21 citations

Aakash Tushar Shah, Honey V. Reddi, Priyadarsini Dasari, James T. Topham, Hyunsoo Hwang +16 more

Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies

JNCI Cancer Spectrum(2020)10.1093/jncics/pkaa034

N/A

0DataRank · unranked

114 citations

Dawn L. Hershman, Raymond U. Osarogiagbon, Anirudh Gothwal, Seerat Anand, Arvind Dasari +4 more

Utility of circulating tumor DNA (ctDNA) in the management of appendiceal adenocarcinoma (AA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.226

N/A

0DataRank · unranked

8 citations

Fadl A. Zeineddine, Abdelrahman Yousef, Julia Dansby, Michael G. White, Michael J. Overman +7 more

A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.140

N/A

0DataRank · unranked

7 citations

Katherine A. Guthrie, Scott Kopetz, Benjamin Tan, Crystal S. Denlinger, Marwan Fakih +15 more

Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps784

N/A

0DataRank · unranked

1 citations

Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Sarah Colby +7 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps258

N/A

0DataRank · unranked

1 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

Goblet cell tumors of the appendix: Clinical and molecular features.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.223

N/A

0DataRank · unranked

0 citations

Zahra Alavi Naini, Mohammad A. Zeineddine, Saikat Chowdhury, Julia Dansby, Aditya More +6 more

Utility of tumor marker levels in predicting survival of patients with appendiceal adenocarcinoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.221

N/A

0DataRank · unranked

0 citations

Aditya More, Mohammad A. Zeineddine, Saikat Chowdhury, Yue Gu, Julia Dansby +7 more

A prospective randomized crossover trial of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.163

N/A

0DataRank · unranked

0 citations

Abdelrahman Yousef, Fadl A. Zeineddine, Mohammad A. Zeineddine, Karen A. Beaty, Lisa C. Scofield +15 more

Data from Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6530433

N/A

0DataRank · unranked

0 citations

Yucai Wang, Muddassir Syed, Alexey V. Sorokin, Oluwadara Coker, Joanne Xiu +17 more

Data from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer

(2023)10.1158/1078-0432.c.6530583

N/A

0DataRank · unranked

0 citations

Jumanah Alshenaifi, Jason Roszik, Ganiraju C. Manyam, Shailesh Advani, Riham Katkhuda +13 more

Data from Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6530433.v1

N/A

0DataRank · unranked

0 citations

Yucai Wang, Muddassir Syed, Alexey V. Sorokin, Oluwadara Coker, Joanne Xiu +17 more

Data from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer

(2023)10.1158/1078-0432.c.6530583.v1

N/A

0DataRank · unranked

0 citations

Jumanah Alshenaifi, Jason Roszik, Ganiraju C. Manyam, Shailesh Advani, Riham Katkhuda +13 more

Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

(2023)10.1158/2159-8290.c.6549433.v1

N/A

0DataRank · unranked

0 citations

Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu‐Chin Fu +29 more

Data from Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer

(2023)10.1158/2767-9764.c.6550830.v1

N/A

0DataRank · unranked

0 citations

Michael J. Overman, Michael Hon‐Wah Lam, Christine M. Parseghian, Benny Johnson, Arvind Dasari +17 more

Prognostic and predictive significance of pre- and post-operative plasma tumor markers in patients with appendiceal adenocarcinoma undergoing cytoreductive surgery: Insights from a single-center study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3539

N/A

0DataRank · unranked

0 citations

Mahmoud Yousef, Mohammad A. Zeineddine, Ichiaki Ito, Saikat Chowdhury, Yue Gu +15 more

Data from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

(2023)10.1158/2767-9764.c.6975005.v1

Top 100%

0DataRank

Top 100%0 citations

Jane V. Thomas, Kaysia Ludford, Jason Willis, Victoria Serpas Higbie, Kanwal Raghav +15 more

Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0019

N/A

0DataRank · unranked

11 citations

Mohammad A. Zeineddine, Betul Beyza Gunes, Andrew J. Pellatt, Mark Knafl, Haifeng Zhu +12 more

Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types

JCO Precision Oncology(2024)10.1200/po-24-00419

N/A

0DataRank · unranked

2 citations

Michael Kahle, Sun‐Hee Kim, Arash Ronaghy, Richard K. Yang, Keyur P. Patel +7 more

Physical activity and dexamethasone for cancer related fatigue: A preliminary placebo controlled randomized control trial.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.12050

N/A

0DataRank · unranked

0 citations

Vicente Valero, Brandon G. Smaglo, Michael J. Overman, Arvind Dasari, Robert A. Wolff +8 more

Mutational and co-mutational landscape of early onset colorectal cancer

Biomarkers(2025)10.1080/1354750x.2024.2447089

N/A

0DataRank · unranked

24 citations

Guglielmo Vetere, Giulia Maddalena, Mahmoud Yousef, Michael G. White, John Paul Shen +14 more

Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials

JAMA Network Open(2023)10.1001/jamanetworkopen.2023.13819

N/A

0DataRank · unranked

12 citations

Joseph Abi Jaoude, Roshal R. Patel, Ramez Kouzy, Timothy A. Lin, Brian De +11 more

Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer

British Journal of Cancer(2020)10.1038/s41416-020-1015-3

N/A

0DataRank · unranked

48 citations

John Paul Shen, Alexandre A. Jácome, Jennifer L. Guerra, Christopher P. Scally, Melissa W. Taggart +7 more

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

Scientific Reports(2020)10.1038/s41598-020-58366-z

N/A

0DataRank · unranked

20 citations

Filip Jankú, Sarina A. Piha‐Paul, Kenneth R. Hess, Russell R. Broaddus, Lidong Liu +11 more

Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin

UNC Libraries(2020)10.17615/kke1-de47

N/A

0DataRank · unranked

0 citations

Thomas LaFramboise, Michael S. Lee, Cathy Eng, David R. Fogelman, Stanley R. Hamilton +14 more

Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer

UNC Libraries(2020)10.17615/cgjy-ks12

N/A

0DataRank · unranked

0 citations

Michael S. Lee, Stanley R. Hamilton, Zhi-Qin Jiang, Jeffrey S. Morris, Scott Kopetz +7 more

Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0331

N/A

0DataRank · unranked

73 citations

Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu-Chin Fu +29 more

ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-2404

N/A

0DataRank · unranked

52 citations

Jumanah Alshenaifi, Jason Roszik, Ganiraju C. Manyam, Shailesh Advani, Riham Katkhuda +13 more

Clinical and Functional Characterization of Atypical KRAS / NRAS Mutations in Metastatic Colorectal Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0180

N/A

0DataRank · unranked

39 citations

Yucai Wang, Muddassir Syed, Alexey V. Sorokin, Oluwadara Coker, Joanne Xiu +17 more

Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.79

N/A

0DataRank · unranked

15 citations

Michael Lam, Xuemei Wang, Michael J. Overman, Benny Johnson, Bryan K. Kee +7 more

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3618

N/A

0DataRank · unranked

7 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.110

N/A

0DataRank · unranked

0 citations

Stefania Napolitano, Van K. Morris, Kunal Rai, John Paul Shen, Jennifer S. Davis +8 more

Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3138

N/A

0DataRank · unranked

0 citations

Daniel D. Karp, Abha Adat, Timothy A. Yap, Siqing Fu, Jordi Rodon Ahnert +12 more

NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience

Clinical and Translational Radiation Oncology(2022)10.1016/j.ctro.2021.12.012

N/A

0DataRank · unranked

68 citations

Ethan B. Ludmir, Anirban Maitra, Bruce D. Minsky, Grace L. Smith, Prajnan Das +14 more

Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts

Frontiers in Oncology(2022)10.3389/fonc.2022.994333

N/A

0DataRank · unranked

20 citations

Alexey V. Sorokin, Lea Bitner, Rebecca Aden, Michael Lam, Ganiraju C. Manyam +8 more

Active surveillance of chemotherapy-related symptom burden in ambulatory cancer patients via the implementation of electronic patient-reported outcomes and sensor-enabled vital signs capture: protocol for a decentralised feasibility pilot study

BMJ Open(2022)10.1136/bmjopen-2021-057693

N/A

0DataRank · unranked

7 citations

Sandra R. DiBrito, Janice Finder, Sanjay Shete, Sanchita Jain, Domenica A. Delgado +5 more

Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRASG12D siRNA in patients with metastatic pancreatic cancer harboring a KRASG12D mutation.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps633

N/A

0DataRank · unranked

39 citations

Valerie S. LeBleu, J. Jack Lee, Brandon G. Smaglo, Dan Zhao, Michael Sangmin Lee +11 more

Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3520

N/A

0DataRank · unranked

9 citations

Eduardo Vilar Sanchez, Ryan Sun, Madhulika Eluri, Van K. Morris, Benny Johnson +11 more

Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3647

N/A

0DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

Randomized phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps643

N/A

0DataRank · unranked

2 citations

Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Shay Bellasea +2 more

Michael J. Overman

Indexed papers

Top data-sharing exemplar

Papers